Thalidomide: From tragedy to promise

Swiss Medical Weekly

Volumn 133, Issue 5-6, 2003, Pages 77-87

  Von Moos, Roger ^a   Stolz, Rahel ^a   Cerny, Thomas ^a   Gillessen, Silke ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Contergan ; Immunomodulation; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BUSULFAN; CARBOPLATIN; CARMUSTINE; CELECOXIB; CISPLATIN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; FLUDARABINE; GEMCITABINE; IRINOTECAN; MELPHALAN; PACLITAXEL; PAMIDRONIC ACID; PENTOXIFYLLINE; PLACEBO; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN; UNINDEXED DRUG;

APHTHOUS ULCER; BEHCET DISEASE; BRADYCARDIA; BURNING SENSATION; CARDIOVASCULAR SYMPTOM; COLITIS; CONGENITAL HEART MALFORMATION; CONSTIPATION; CROHN DISEASE; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; EDEMA; ENTERITIS; EOSINOPHILIA; ERYTHEMA NODOSUM; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GLIOMA; HEADACHE; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOMODULATION; INCREASED APPETITE; KAPOSI SARCOMA; KIDNEY CARCINOMA; LETHARGY; MELANOMA; METASTASIS; MOOD DISORDER; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PAIN; PALLIATIVE THERAPY; PARESTHESIA; PERIPHERAL NEUROPATHY; PHOCOMELIA; PROSTATE CANCER; PRURITUS; RASH; REMISSION; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SEDATION; SHORT SURVEY; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; SPINA BIFIDA; SYSTEMIC LUPUS ERYTHEMATOSUS; TEMPERATURE SENSITIVITY; TERATOGENICITY; TREMOR; UROGENITAL ULCER; VERTIGO; WALDENSTROEM MACROGLOBULINEMIA; XEROSTOMIA;

EID: 0037425714     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (104)

1. Mc Bride WG. Thalidomide and congenital abnormalities. Lancet 1961/II:1358.
2. Lenz W. Thalidomide and congenital abnormalities. Lancet 1961;I:45.
3. Lenz W. A short history of thalidomide embryopathy. Teratology 1988;38:203-15.
4. Wiedemann HR. Hinweis auf eine derzeitige Häufung hypound aplastischer Fehlbildungen der Gliedmassen. Med Welt 1988;37:1863.
5. Iyer CG, Languillon J, Ramanujam K, Tarabini-Castellani G, De las Aguas JT, Bechelli LM, et al. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ 1971;45:719-32.
6. Nirenberg A. Thalidomide: when everything old is new again. Clin J Oncol Nurs 2001;5:15-8.
7. Orioli IM, Freire BM. Availability of teratogens in Brazil: misoprostol and thalidomide. Departemento de genetica, univeridade federal do rio de janeiro, Brazil.
8. Eriksson T, Bjorkman S, Roth B, Fyge A, Hoglund P. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 1995;7:44-52.
9. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 2001;57:365-76.
10. Schumacher H, Smith RL, Williams RT. The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol 1965;25:338-51.
11. Meierhofer CH, Dunzendorfer S, Wiedermann CHJ. Theoretical basis for the activity of thalidomide. Bio Drugs 2001;15:681-703.
12. Stirling DI. Pharmacology of thalidomide. Seminars in Hematology 2000;37:5-14.
13. Lutwak-Mann C, Schmid K, Keberle H. Thalidomide in rabbit semen. Nature 1967;214:1018-20.
14. Figg WD, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, et al. Pharmacokinetics of thalidomide in an elderly prostate cancer population. J Pharm Sci 1999;88:121-5.
15. Amato RJ. Thalidomide: An antineoplastic agent. Curr Oncol Rep 2002;4:56-62.
16. Gad SM, Shannon EJ, Krotoski WA, Hastings RC. Thalidomide induces imbalances in T-lymphocyte subpopulations in the circulating blood of healthy males. Lepr Rev 1985;56:35-39.
17. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187:1885-92.
18. McHugh SM, Rifkin IR, Deighton J, Wilson AB, Lachmann PJ, Lockwood CM, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995;99:160-7.
19. Keenan RJ, Eiras G, Burckart GJ, Stuart RS, Hardesty RL, Vogelsang G, et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. Transplantation 1991;52:908-10.
20. Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Curr Opin Oncol 2000;12:564-73.
21. Nogueira AC, Neubert R, Helge H, Neubert D. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci 1994;55:77-92.
22. Dunzendorfer S, Schratzberger P, Reinisch N, Kahler CM, Wiedermann CJ. Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine- and endotoxin-activated endothelium. Naunyn Schmiedebergs Arch Pharmacol 1997;356:529-35.
23. Hastings RC, Morales MJ. The effect of thalidomide on neutrophil function. Int J Lepr other Mycobact Dis 1978;46:120.
24. Fauré M, Lejeune JP, Gaucherand M, Thivolet J. PMN leukocytes chemotaxis: inhibition by thalidomide. Pathol Biol 1981;29:601-4.
25. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703.
26. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.
27. Turk BE, Jiang H, Liu JO. Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibitory action on tumor necrosis factor production. Proc Natl Acad Sci USA 1996;93:7552-7556.
28. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001;276:22382-7.
29. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kB. J Clin Invest 2001;3, 107:241-246.
30. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Flockhart DA, et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997;159:5157-61.
31. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5.
32. Mellin GW, Katzenstein M. The saga of thalidomide (concluded): Neuropathy to embryopathy with case reports of congenital anomalies. N Engl J Med 1962;267:1238-1244.
33. Sherman M, Strauss S. A twenty-five year perspective. Food Drug Cosmetic Law J 1986;41:458-466.
34. Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 2001 Aug;24:1050-7.
35. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal V, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98:1614-1615.
36. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, et al. A randomized phase II trial of docetaxel (Taxotere) plus thalidomide in androgen-independent prostate cancer. Seminars in Oncology 2001;28(4 Suppl 15):62-66.
37. Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide. Focus on palliative care. Drugs 2000;60:273-292.
38. Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001 Jul;12:991-5.
39. Woodcock J. Supervisory review of NDA. 1998:20-785.
40. Sheskin J. Thalidomide in the treatment of lepra reactions. J Clin Pharmacol 1965;6:303-6.
41. Hastings RC, Trautman JR, Enna CD, Jacobson RR. Thalidomide in the treatment of erythema nodosum leprosum. With a note on selected laboratory abnormalities in erythema nodosum leprosum. Clin Pharmacol Ther 1970;11:481-7.
42. Pearson JM, Vedagiri M. Treatment of moderately severe erythema nodosum leprosum with thalidomide-a double-blind controlled trial. Lepr Rev 1969;40:111-6.
43. Waters MF. An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum. Lepr Rev 1971;42:26-42.
44. Yazici H, Yurdakul S, Hamuryudan V. Behcet disease. Curr Opin Rheumatol 2001;13:18-22.
45. Postema PT, den Haan P, van Hagen PM, van Blankenstein M. Treatment of colitis in Behcet's disease with thalidomide. Eur J Gastroenterol Hepatol 1996;8:929-31.
46. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:443-50.
47. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999;117:1271-7.
48. Wettstein AR, Meagher AP. Thalidomide in Crohn's disease. Lancet 1997;350:1445-6.
49. Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999;117:1278-87.
50. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis - the thalidomide experience. J Rheumatol 1989;16:158-63.
51. Keesal N, Wasserman MJ, Bookman A, Lapp V, Weber DA, Keystone EC. Thalidomide in the treatment of refractory rheumatoid arthritis. J Rheumatol 1999;26:2344-7.
52. Huizinga TW, Dijkmans BA, van der Velde EA, van de Pouw Kraan TC, Verweij CL, Breedveld FC. An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis 1996;55:833-6.
53. Estines O, Revuz J, Wolkenstein P, Bressieux JM, Roujeau JC, Cosnes A. Sarcoidosis: thalidomide treatment in ten patients. Ann Dermatol Venereol 2001;128:611-3.
54. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995;32(5 Pt 2):866-9.
55. Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE. Thalidomide for chronic sarcoidosis. Chest 2002;122:227-32.
56. Ravot E, Lisziewicz J, Lori F. New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide. Drugs 1999;58:953-63.
57. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997;336:1487-93.
58. Sato EI, Assis LS, Lourenzi VP, Andrade LE. Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Rev Assoc Med Bras 1998;44:289-93.
59. Walchner M, Meurer M, Plewig G, Messer G. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol 2000;39:383-8.
60. Versapuech J, Beylot-Barry M, Doutre MS, Beylot C. Subacute cutaneous lupus. Evolutive and therapeutic features of a series of 24 cases. Presse Med 2000;29:1596-9.
61. Duong DJ, Spigel GT, Moxley RT 3rd, Gaspari AA. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 1999;135:1079-87.
62. Parker PM, Chao N, Nademanee A, O'Donnell MR, Schmidt GM, Snyder DS, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995;86:3604-3609.
63. Gnassia AM, Gnassia T, Bonvalet D, Puissant A, Goudal H. Histiocytose X avec "granuloma eosinophile vulvaire". Effect spectaculaire de la thalidomide. Ann Dermatol Venerol 1987;114:1387-1389.
64. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-71.
65. Rajkumar SV, Witzi RE. A review of angiogenesis and anti-angiogeneric therapy with thalidomide in multiple myeloma. Cancer Treat Rev 2000;26:351-362.
66. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000;75:897-901.
67. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Hematol 2000;109:89-96.
68. Barologie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory muliple myeloma after single agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-4.
69. Dimopoulos MA, Zomas A, Viniou NA, Grigoraki V, Galani E, Matsouka C, et al. Treatment of Waldenstrom's macroglobulimemia with thalidomide. J Clin Oncol 2001;19:3596-3601.
70. Leleu X, Magro L, Fawaz A, Bauters F, Facon T, Yakoub-Agha I. Efficacy of a low dose of thalidomide in advanced multiple myeloma. Blood 2002;100:1519-20.
71. Blade J, Perales M, Rosinol L, Tuset M, Montoto S, Esteve J, et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Hematol 2001;113:422-424.
72. Avigdor A, Raani P, Levi I, Hardan I, Ben-Bassat I. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma 2001;42:683-687.
73. Rajkumar SV, Fonseca R, Dispensieri A, et al. A phase II trial of thalidomide in the treatment of relapsed multiple myeloma (MM) with laboratory correlative studies. Blood 2000;96:168a, Abstract 723.
74. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-216.
75. Osman K, Comenzo R, Rajkumar SF. Deep vein thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001;344:1951-1952.
76. Strupp C, Germing U, Aviado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002;16:1-6.
77. Badros A, Morris C, Zangari M, Barlogie B, Tricot G. Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia. Leuk Lymphoma 2002;43:1267-1271.
78. Steins MB, Padro T, Bieker R, Ruiz S, Kropff M, Kienast J, et al. Efficacy and safety of thalidomide in patients with acute myeloid leukaemia. Blood 2002;99:834-839.
79. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, et al. Phase II trial of antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18:708-715.
80. Marx GM, Pavlakis N, McCowatt S, Boyle FM, Levi JA, Bell DR, et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. Neurooncol 2001;54:31-8.
81. Bell D, Biggs M, Boyle F, Cook R, Freilich R, Levi J, et al. Phase II study of thalidomide as an anti-angiogenic agent in the treatment of recurrent glioblastoma multiforme. Proc Am Soc Clin Oncol 2000;Abstract 613.
82. Fine HA, Maher EA, Wen PY, Batchelor T, Viscosi E, Figg W. Phase II trial of thalidomide and BCNU in recurrent high grade gliomas. Proc Am Soc Clin Oncol 2001;Abstract 218.
83. Fife K, Howard MR, Gracie F, Phillips RH, Bower M. Activity of thalidomide in AIDS related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998;9:751-55.
84. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, et al. Activity of thalidomide in AIDS-related Kaposis sarcoma. J Clin Oncol 2000;18:2593-602.
85. Lewi D, Loss M, Politi P, Reboredo G, Schwartsmann G, Vujacich C. Phase I trail of thalidomide in AIDS-related Kaposi sarcoma. Proc Am Soc Clin Oncol 1998;Meeting-Abstract.
86. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, et al. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Brit J Cancer 2000;82, 4:812-17.
87. Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002;1:302-6.
88. Stebbing J, Benson C, Eisen T, Pyle L, Smalley K, Bridle H, et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 2001;85:953-8.
89. Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S, et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002;13:1029-35.
90. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888-93.
91. Dixon SC, Kruger EA, Bauer KS, Wigg WD. Thalidomide upregulates prostate-specific antigen secretion from LNCaP cells. Cancer Chemother Pharmacol 1999;43 (Suppl):78-84.
92. Hwu WJ, Panageas K, Krown SE, Chapman PB, Livingston P, Williams LJ, et al. Phase I study of temozolomide and thalidomide in the treatment of metastatic melanoma. J Clin Oncol 2001:Abstract1424.
93. Hwu WJ, Krown SE, Panageas K, Menell JH, Chapman PB, Livingston PO, et al. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol 2002;11:2607-9.
94. Pavlick AC, Oratz R, Bailes A, Farrell K, Volm M, Muggia F, et al. A phase II trial of DTIC with thalidomide in metastatic melanoma. J Clin Oncol 2002;Abstract 1393.
95. Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock T, et al. Phase II study of thalidomide in patients (pts) with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2002;21, 2:p 97b, Abstract 2002, 38th Annual Meeting, May 18-21 2002, Orlando FL.
96. Xu Y, Ellison C, Martin E, Young D, Campbell J, Vinci L, et al. A phase II study of thalidomide in metastatic neuroendocrine tumors. Proc Am Soc Clin Oncol 2002;21, 2:p 30b, Abstract 1931, 38th Annual Meeting, May 18-21 2002, Orlando FL.
97. Pavlakis N, Williams G, Harvey R, Aslani A, Abraham R, Wheeler H. Thalidomide alone and in combination with cisplatin/gemcitabine chemotherapy for malignant mesothelioma (MM): preliminary results from two phase II studies. Proc Am Soc Clin Oncol 2002;21, 2:p19b, Abstract 1885 38th Annual Meeting, May 18-21 2002, Orlando FL.
98. Howe M. Thalidomide for treatment of mesothelioma. Lancet Oncol 2001;2:253.
99. Govindarajan R, Heaton KM, Broadwater R, Zeitlin A, Lang NP, Hauer-Jensen M. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 2000;356:566-7.
100. Govindarajan R. Irinotecan and thalidomide in metastatic colorectal cancer. Oncology (Huntingt)2000;14:29-32.
101. Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crewford JG, et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000;18:2710-17.
102. Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, ElNaggar AK, et al. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 2001;92:2364-73.
103. Brophy D, Hammes L, Kim KM, Larson M, Mehta M, Merchant J, et al. Pilot and safety trial of carboplatin, paclitaxel and thalidomide in advanced non-small cell lung cancer. J Clin Oncol 2000:Abstract 2130.
104. Boyer MJ, Lim R, Clarke S, Milward J, Wong E. Phase II trial of Thalidomide in unresectable hepatocellular carcinoma (HCC) - a cancer therapeutics group (CTRG) study. Proc Am Soc Clin Oncol 2001;20, 2:p 133b, Abstract 2282, 37th Annual meeting, May 12-15 2001, San Francisco CA.